Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia

Global and quantitative assessment

Mary C. See, Audrey H. Birnbaum, Clyde B. Schechter, Marvin M. Goldenberg, Keith J. Benkov

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine. Global and quantitative pain assessments were done before and after each treatment period. The quantitative assessment was calculated based on the abdominal pain score that was the sum of three components. Based on the global evaluation, there was a clear benefit of famotidine over placebo (68% vs 12%). Using the quantitative assessment, however, the mean improvement of the score using famotidine versus placebo was not statistically significant (3.37 ± 3.53 vs 1.66 ± 2.7). There was a significant improvement in this score during the first treatment period regardless of medication used (period effect: P = 0.05). A subset of patients with peptic symptoms demonstrated a significant drug effect that outweighed the period effect (drug effect: P = 0.01; period effect: P = 0.02). We conclude that famotidine subjectively improves the symptoms of children with recurrent abdominal pain but not objectively using the derived score. However, famotidine is significantly more effective than placebo among children with peptic symptoms. The use of this simple scoring scale may facilitate selecting those children who will benefit from H2-receptor antagonist therapy.

Original languageEnglish (US)
Pages (from-to)985-992
Number of pages8
JournalDigestive Diseases and Sciences
Volume46
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Famotidine
Dyspepsia
Abdominal Pain
Placebos
Histamine H2 Receptors
Digestion
Pain Measurement
Pharmaceutical Preparations
Therapeutics

Keywords

  • Dyspepsia
  • Famotidine
  • H-receptor antagonist
  • Recurrent abdominal pain

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia : Global and quantitative assessment. / See, Mary C.; Birnbaum, Audrey H.; Schechter, Clyde B.; Goldenberg, Marvin M.; Benkov, Keith J.

In: Digestive Diseases and Sciences, Vol. 46, No. 5, 2001, p. 985-992.

Research output: Contribution to journalArticle

@article{bf8ada4e2b9e4b88aeee4072e3372049,
title = "Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: Global and quantitative assessment",
abstract = "To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine. Global and quantitative pain assessments were done before and after each treatment period. The quantitative assessment was calculated based on the abdominal pain score that was the sum of three components. Based on the global evaluation, there was a clear benefit of famotidine over placebo (68{\%} vs 12{\%}). Using the quantitative assessment, however, the mean improvement of the score using famotidine versus placebo was not statistically significant (3.37 ± 3.53 vs 1.66 ± 2.7). There was a significant improvement in this score during the first treatment period regardless of medication used (period effect: P = 0.05). A subset of patients with peptic symptoms demonstrated a significant drug effect that outweighed the period effect (drug effect: P = 0.01; period effect: P = 0.02). We conclude that famotidine subjectively improves the symptoms of children with recurrent abdominal pain but not objectively using the derived score. However, famotidine is significantly more effective than placebo among children with peptic symptoms. The use of this simple scoring scale may facilitate selecting those children who will benefit from H2-receptor antagonist therapy.",
keywords = "Dyspepsia, Famotidine, H-receptor antagonist, Recurrent abdominal pain",
author = "See, {Mary C.} and Birnbaum, {Audrey H.} and Schechter, {Clyde B.} and Goldenberg, {Marvin M.} and Benkov, {Keith J.}",
year = "2001",
doi = "10.1023/A:1010793408132",
language = "English (US)",
volume = "46",
pages = "985--992",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "5",

}

TY - JOUR

T1 - Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia

T2 - Global and quantitative assessment

AU - See, Mary C.

AU - Birnbaum, Audrey H.

AU - Schechter, Clyde B.

AU - Goldenberg, Marvin M.

AU - Benkov, Keith J.

PY - 2001

Y1 - 2001

N2 - To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine. Global and quantitative pain assessments were done before and after each treatment period. The quantitative assessment was calculated based on the abdominal pain score that was the sum of three components. Based on the global evaluation, there was a clear benefit of famotidine over placebo (68% vs 12%). Using the quantitative assessment, however, the mean improvement of the score using famotidine versus placebo was not statistically significant (3.37 ± 3.53 vs 1.66 ± 2.7). There was a significant improvement in this score during the first treatment period regardless of medication used (period effect: P = 0.05). A subset of patients with peptic symptoms demonstrated a significant drug effect that outweighed the period effect (drug effect: P = 0.01; period effect: P = 0.02). We conclude that famotidine subjectively improves the symptoms of children with recurrent abdominal pain but not objectively using the derived score. However, famotidine is significantly more effective than placebo among children with peptic symptoms. The use of this simple scoring scale may facilitate selecting those children who will benefit from H2-receptor antagonist therapy.

AB - To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine. Global and quantitative pain assessments were done before and after each treatment period. The quantitative assessment was calculated based on the abdominal pain score that was the sum of three components. Based on the global evaluation, there was a clear benefit of famotidine over placebo (68% vs 12%). Using the quantitative assessment, however, the mean improvement of the score using famotidine versus placebo was not statistically significant (3.37 ± 3.53 vs 1.66 ± 2.7). There was a significant improvement in this score during the first treatment period regardless of medication used (period effect: P = 0.05). A subset of patients with peptic symptoms demonstrated a significant drug effect that outweighed the period effect (drug effect: P = 0.01; period effect: P = 0.02). We conclude that famotidine subjectively improves the symptoms of children with recurrent abdominal pain but not objectively using the derived score. However, famotidine is significantly more effective than placebo among children with peptic symptoms. The use of this simple scoring scale may facilitate selecting those children who will benefit from H2-receptor antagonist therapy.

KW - Dyspepsia

KW - Famotidine

KW - H-receptor antagonist

KW - Recurrent abdominal pain

UR - http://www.scopus.com/inward/record.url?scp=0035035953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035035953&partnerID=8YFLogxK

U2 - 10.1023/A:1010793408132

DO - 10.1023/A:1010793408132

M3 - Article

VL - 46

SP - 985

EP - 992

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 5

ER -